Understanding RSV and Why This Vaccine is a Game Changer

respiratory Syncytial Virus (RSV) is often dismissed as a childhood illness, but it poses a important threat to older adults. Before November 13, 2025, there was no approved vaccine to protect this vulnerable population. Each year, RSV leads to approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults 65 years and older in the United States. The impact extends beyond mortality; RSV can exacerbate existing conditions like heart failure and chronic obstructive pulmonary disease (COPD), leading to a diminished quality of life.

The newly approved vaccine, Arexvy, developed by GSK, targets the RSV-A strain, which is responsible for the vast majority of RSV-related illnesses. Clinical trial data published in the New England Journal of medicine on november 13, 2025, demonstrated a remarkable 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTI) in adults 60 years and older. This means that among those vaccinated, the risk of developing severe RSV illness was significantly reduced.

How the Arexvy Vaccine Works

Arexvy is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus, preventing infection or reducing the severity of illness. Unlike some other vaccines, Arexvy does *not* contain a live virus, making it safe for individuals with weakened immune systems.

The clinical trial involved over 12,600 adults aged 60 years and older.participants were randomly assigned to receive either the Arexvy vaccine or a placebo. The study followed participants for one RSV season, monitoring for the development of RSV-associated LRTI, defined as symptoms like cough, fever, and shortness of breath requiring medical intervention. The 82.6% efficacy rate was observed across all age groups within the study population.

Side Effects and Safety Considerations

As with any vaccine, Arexvy can cause side effects. The most commonly reported side effects in clinical trials were pain at the injection site, fatigue, muscle aches, headache, and joint pain. These side effects were generally mild to moderate in severity and resolved within a few days. Serious adverse events were rare and not definitively linked to the vaccine.

However, it’s important to note that a small number of participants in the clinical trial experienced Guillain-Barré syndrome (GBS) following vaccination. While a causal relationship has not been established, the FDA is requiring GSK to conduct post-market surveillance to further investigate this potential risk.Individuals with a history of GBS should discuss the risks and benefits of vaccination with their healthcare provider.

Who Should Get the RSV Vaccine?

The FDA approved Arexvy for adults aged 60 years and older, but the CDC’s recommendations will determine who should *routinely* receive the vaccine. It is anticipated that the CDC will prioritize vaccination for those at highest risk of severe RSV illness, including